Saturday, June 1, 2013

Colorado Board of Pharmacy Refers Cases Against to Pharmerica and Wedgewood Village Pharmacy to State of Residence; in another case against Wedgewood Board votes unanimously to refer case for discipline


Pharmerica, OSP 5137 2012-6857
The Board voted unanimously to table further consideration of this case and refer the matter to the Indiana Board of Pharmacy.
Wedgewood Village Pharmacy, OSP 5464 2012-6859
The Board voted unanimously to table further consideration of this case and refer the matter to the New Jersey State Board of Pharmacy.



Wedgewood Village Pharmacy, OSP 5464 2012-6732
The Board voted unanimously to refer the case to Executive Session.
After Executive Session, the Board voted unanimously to refer the case for discipline.



quoted from here

Colorado Board of Pharmacy Issues Complaint Against Pencol Compounding Pharmacy


Pencol Compounding Pharmacy, PDO 154
The Board reviewed an Agenda Memorandum from Ms. Martin and Mr. Gassen regarding recent inspections of Pencol Compounding Pharmacy. The Board voted unanimously to initiate a complaint against Pencol Compounding Pharmacy’s prescription drug outlet registration.

quoted from here

KUDOS to Colorado State Board of Pharmacy for Reaching out to Colorado Medical Board and the Colorado State Board of Veterinary Medicine for additional practitioners wishing to join the Compounding Task Force!!!


California Board of Pharmacy files Complaints Against Indio Medical Pharmacy, La Jolla Discount Pharmacy, Southern California Compound Pharmacy, Westside Pharmacy--All Relating To Compounding Issues


Site Licenses
Indio Medical Pharmacy, PHY 21267, Administrative Case AC 4569
Indio, CA
Accusation Filed 4/4/2013, Case Pending.
View the accusation
La Jolla Discount Pharmacy, PHY 38070, Administrative Case AC 4572
La Jolla, CA
Accusation Filed 4/4/2013, Case Pending.
View the accusation
Southern California Compounding Pharmacy, LLC , LSC 99510, Administrative Case AC 4671
San Diego, CA
Accusation Filed 04/2012; Case Pending
View the accusation
Westside Pharmacy, PHY 15178, and LSC 99245, Administrative Case AC 4385
Fresno, CA
Accusation Filed 4/28/2013, Case Pending.
View the accusation

Idaho Board of Pharmacy 2013 Pharmacy Administrative Rule and Statue Changes-Several Relate to Compounding


2013 Pharmacy Administrative Rule and Statute
Changes
On April 4, 2013, four dockets of rule changes took effect, as
detailed in the March 2013 Newsletter. On July 1, 2013, the following
changes to an administrative rule and sections of Idaho Code
will become effective. Copies of the pertinent docket of rules and
bills are available on the Idaho State Board of Pharmacy’s Web site.
Engrossed versions of Idaho Code and the Board’s administrative
rules are expected to be available later this summer.
House Bill 239 gives the Board statutory authority to address
compounding and the distribution of compounded drug product
in rule, as well as extending to all pharmacies the sale of minimal
quantities of prescription drugs to licensed practitioners for office
use, without required wholesale licensure. Please see the Board’s
Web site for a draft version of such subsequent rules; the Board is
currently accepting public comment on this draft.
House Bill 16 allows a pharmacist or practitioner to furnish another
pharmacist or practitioner information legally obtained from
the Board’s Prescription Monitoring Program database.
House Bill 17 (HB 17) mainly expands the practice of pharmacy
into Idaho, with considerably more regulation of such persons,
practices, and practice sites; however, the bill also deletes outdated
practices and contains several non-substantive changes. HB 17
merges the Out-of-State Mail Service Pharmacy Act into the Idaho
Pharmacy Act, and defines central drug outlet, central pharmacist,
mail service pharmacy, nonresident, pharmacist-in-charge (PIC),
and centralized pharmacy services, which means the processing by
a central drug outlet or central pharmacist of a request from another
pharmacy to fill, refill, or dispense a prescription drug order, perform
processing functions, or provide cognitive or pharmaceutical care
services. Each function may be performed by the same or different
persons and at the same or different locations. All persons and
business entities engaging in the practice of pharmacy into Idaho,
including but not limited to pharmaceutical care services, must be
licensed and registered, except nonresident pharmacists practicing
pharmacy into Idaho who are employed by and practicing for an
Idaho registered nonresident mail service pharmacy. All nonresident
mail service pharmacies and central drug outlets must also have a
PIC or director who is licensed or registered by the Board.
Please note that nonresident pharmacist registration is a lower
standard when compared to pharmacist licensure, as pharmacist
registration does not require an applicant to reciprocate through
the National Association of Boards of Pharmacy® or pass an Idahobased
Multistate Pharmacy Jurisprudence Examination®. However,
the Board may take any action against a nonresident pharmacist
registrant that it can take against a pharmacist licensee for violations
of the laws of Idaho or the state in which the pharmacist resides.
Additionally, the Board may take any action against a nonresident
drug outlet that it may take against its agents and employees. A successful
applicant for a nonresident central drug outlet, mail service
pharmacy, or pharmacist registration or licensure must comply with
the Board’s laws and rules unless compliance would violate the laws
or rules in the state in which the registrant is located, except a technician
shall not exceed the practice limitations for technicians in Idaho
and a pharmacist shall only substitute and generically select drug
products in accordance with Idaho law and shall not exceed Idaho’s
pharmacy staffing ratio. Additionally, the Board may issue an order
likewise suspending, revoking, restricting, or otherwise affecting
the license or registration in Idaho, without further proceeding, as
Drug Enforcement Administration or another state licensing board
with authority over a licensee’s or registrant’s professional license
or registration has issued. Also, if the Board conducts a nonresident
inspection, the nonresident drug outlet shall pay the costs of such
inspection. Lastly, HB 17 reestablishes the original out-of-state mail
service pharmacy fees for all nonresident mail service pharmacies
and central drug outlets: $500 for initial registration and $250 for
renewal.
Docket 27-0101-1205 reiterates some of HB 17 for ease of reading
the rules. Remote office location is defined and allowed with certain
security requirements. While the category of “telepharmacy across
state lines” is absorbed into the new nonresident rule and statute, the
existing $250 registration fee for “telepharmacists across state lines”
is expanded to all pharmacist registrants, but pharmacist licensure
fees remain unchanged. New Rule 029 details which pharmacists
practicing pharmacy in or into Idaho need to be registered or licensed.
The registration category of “telepharmacist across state
lines,” who practice from nonresident institutional pharmacies, is
expanded to all nonresident pharmacists who practice from within
a pharmacy. Unless statutorily exempted (a nonresident pharmacist
working for a mail service pharmacy) or a nonresident PIC or director,
all other pharmacists practicing pharmacy in or into Idaho
must be Idaho licensed, including those practicing from a central
drug outlet that is not a pharmacy and remote office locations. Upon
applying, nonresident central drug outlets and mail service pharmacies
must submit an executive summary describing the centralized
pharmacy services to be performed.
Docket 27-0101-1205 also addresses practice standards. For
example, Rule 320 mandates that the independent practice of
pharmacy is not to be construed to excuse compliance with the
rules governing centralized pharmacy services. The independent
practice of pharmacy rule’s minimal standards are designed to
recognize and regulate pharmacist activities outside of a drug
outlet or institutional facility, such as at a health fair. Rule 610’s
expanded regulation pertains to centralized pharmacy servicessuch as
providing cognitive services for an institutional pharmacy,
remote data entry, and central fill. A pharmacy may centralize
pharmacy services to another Idaho registered business entity, to
be performed at a pharmacy, central drug outlet, or remote office
location, pursuant to a written contract, policies and procedures,
certain training, appropriate communication, a common electronic
file (or other secure technology), a continuous quality improvement
program, audit trail documentation, and privacy considerations. For
an institutional pharmacy, centralized pharmacy services are only
allowed for the limited purpose of ensuring that drugs or devices
are attainable to meet the immediate needs of patients or residents
of the institutional facility.
quoted from Idaho Board of Pharmacy June 2013 Newsletter


Iowa Board of Pharmacy Reminder That All Iowa Pharmacies Respond to the Following Survey


Compounding Survey
The Board has requested that all Iowa pharmacies respond
to the following survey. Responses may be sent via e-mail to
terry.witkowski@iowa.gov. Please respond by July1. Are you compounding prescription or over-the-counter
(OTC) drugs at your pharmacy?
2. If you are engaged in compounding, what type of compounding
is being done (eg, sterile, nonsterile, OTC)?
3. Does your pharmacy ship compounded products to
other states?
4. Are your pharmacists, technicians, or the pharmacy
itself accredited?
5. If accredited, what is the name of the accrediting body?
6. Are all compounds dispensed pursuant to a patientspecific
prescription?
7. If compounds are distributed for “office use,” what is the
percentage of total compounded prescription volume?
8. Does your pharmacy have a separate compounding
area within the prescription department? If so, please
describe.
9. Are you compounding any commercially available
products? If so, what products are being produced and
in what quantities?
10. Does your pharmacy document and track adverse drug
events associated with compounded drug products?

quoted from Iowa Board of Pharmacy June 2013 Newsletter

Iowa Board of Pharmacy Clarification on Compounded Preparations


Clarification on Compounded
Preparations
Iowa Board of Pharmacy Subrule 657 IAC 20.3(1) allows
the compounding of a commercially available product only if
it is necessary to meet the unique medical need of a patient.
The complete text of that subrule is provided below. Pursuant
to 657 IAC 20.2, all compounding, regardless of the type
of product, is to be done pursuant to a prescription and the
prescription must be based on a valid pharmacist/patient/prescriber
relationship. Subrule 657 IAC 20.3(4) allows for the
preparation of non-patient-specific products for “office use” if
the product is administered to an individual patient by the prescribing
practitioner in a professional practice setting. Subrule
657 IAC 20.3(4) also allows a pharmacy to prepare and sell
to a hospital pharmacy a compounded drug product prepared
pursuant to a prescriber’s authorization for administration to a
specific patient. Iowa law and rules have never allowed a pharmacy
to prepare and sell to a hospital pharmacy compounded
preparations in the absence of a prescription. Such activity is
considered manufacturing. This would include the preparation
of sterile products such as outsourced compounded solutions,
IVs, or injectables.
657 Iowa Administrative Code – 20.3(1) Compounding
commercially available product. Based on the
existence of a pharmacist/patient/prescriber relationship
and the presentation of a valid prescription,
pharmacists may compound, for an individual patient,
drug products that are commercially available in the
marketplace, if the compounded product is changed
to produce for that patient a significant difference, as f
authorized by the prescriber, between the compounded
drug and the comparable commercially available drug
product, or if use of the compounded product is in the
best interest of the patient. “Significant difference”
would include the removal of a dye for a medical reason
such as an allergic reaction. When a compounded
product is to be dispensed in place of a commercially
available product, the prescriber and patient shall
be informed that the product will be compounded

quoted from Iowa Board of Pharmacy June 2013 Newsletter

Kentucky Board of Pharmacy Issues a Reminder About Compounding Issues


Compounding Issues
In line with FDA’s statement, pharmacists are reminded that 20 CSR
2220-2.200(9) provides:
Compounding of drug products that are commercially available
in the marketplace or that are essentially copies of commercially
available Federal [Food and] Drug Administration (FDA) approved
drug products is prohibited. There shall be sufficient
documentation within the prescription record of the pharmacy
of the specific medical need for a particular variation of a commercially
available compound.

quoted from Kentucky Board of Pharmacy June 2013 Newsletter

Kentucky Board of Pharmacy Hires a New Pharmacy and Drug Inspector


New Pharmacy and Drug Inspector
Amanda Harding, RPh, began working as a pharmacy and drug
inspector for the Board on May 1, 2013. She is a 2008 graduate of the
University of South Carolina College of Pharmacy. Amanda’s pharmacy
background consists primarily of working in community pharmacy. She
was a pharmacy manager for Walgreens from 2009 to 2013. She is a
resident of Louisville, KY, and will be inspecting Louisville and some
surrounding counties.

quoted from Kentucky Board of Pharmacy June 2013 Newsletter

New Mexico Board of Pharmacy Proposed Changes to Compounding Rules


During the April 18-19, 2013, New Mexico Board of Pharmacy
meeting, three regulation changes were made. One of  these
regulation changes is discussed below and relates to compounding

16.19.30.9 NMAC – Compounding of Nonsterile Pharmaceuticals;
Operational Standards. This regulation revision
states that a pharmacy may no longer compound for a prescriber’s
office use. The wording allowing for office use compounding
was removed from the regulation. A compounded
medication may be sold by a pharmacy by prescription only.
The labeled compounded product is sold after receipt of a
valid prescription is issued to a specific patient.
All Board regulation changes are heard in open session
during Board meetings. Links to the proposed changes are
available online. Go to the Board Web site and click on the
agenda for the Board meeting. There you will find a link to
a proposed regulation change. Public and professional comments
are welcome. Please submit comments to the Board
through written correspondence at least 15 days prior to the
Board meeting, or you may appear in person to express your
opinion.
quoted from New Mexico Board of Pharmacy June 2013 Newsletter